Epitalon vs Pinealon: Comparing Two Khavinson Bioregulator Peptides

What are peptide bioregulators?

Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology spent decades on polypeptide extracts of animal organs, such as the pineal preparation epithalamin and the thymic preparation thymalin. From the amino-acid composition of those extracts they designed short synthetic peptides, such as dipeptides for the thymus and tetrapeptides for the pineal gland, heart, liver and brain cortex, and reported that each stimulated growth of explants from its matching organ¹.

The group's peptide theory of aging holds that aging involves changes in gene expression that reduce the synthesis of regulatory peptides, and that supplying such peptides could restore normal function¹. It is the framework of one research school, and both Epitalon and Pinealon papers interpret their results within it. Readers should keep that context in mind when weighing the findings below.

Epitalon vs Pinealon at a glance

The table compares the two peptides on origin, structure, targets and evidence. Each row is discussed, with citations, in the sections that follow.

Epitalon research: telomeres, melatonin and life span

Epitalon was synthesized on the basis of the amino-acid composition of epithalamin and is known in the literature as Epitalon, Epithalon or Epithalone². In 2003 Khavinson's group reported that it induced expression of the telomerase catalytic subunit, telomerase activity and telomere elongation in telomerase-negative human fetal fibroblasts³. In 2025 an independent group at Brunel University London reported telomere extension through hTERT and telomerase upregulation in normal human cells, and through alternative lengthening of telomeres (ALT) in breast cancer cell lines⁴.

In whole animals, female SHR mice given Epitalon over their lifetime showed no change in mean life span, but fewer bone-marrow chromosome aberrations and a longer life span among the last 10% of survivors⁵. In old rhesus monkeys, Epitalon raised night-time melatonin and lowered basal glucose and insulin⁶. An in vitro perifusion study of rat pineal glands in Paris, by contrast, found no effect on melatonin secretion in young or old animals⁷.

Pinealon research: neurons under stress

Pinealon work has focused on nerve cells rather than on the pineal gland. In rat cerebellar granule cells, neutrophils and PC12 cells under oxidative stress, Pinealon limited reactive oxygen species and necrotic death in a concentration-dependent way and delayed ERK1/2 activation⁸. In rats with diet-induced hyperhomocysteinemia during pregnancy, offspring of dams given Pinealon performed better in spatial learning tests, and their cerebellar neurons were more resistant to oxidative stress⁹.

In models of amyloid synaptotoxicity, EDR restored the number of mushroom-type dendritic spines in cultured mouse hippocampal neurons¹⁰ and prevented dendritic spine loss in 5xFAD transgenic mice¹¹. These endpoints describe synaptic structure in disease models; they are not measures of cognition in people.

Where Epitalon and Pinealon overlap

The two peptides have been tested side by side in a few recent St. Petersburg studies. In neurons transdifferentiated from the skin fibroblasts of elderly donors, EDR, AEDG and a third peptide (KED) all increased dendritic branching; EDR also reduced oxidative DNA damage, while the tripeptides did not change mitochondrial or lysosomal activity or p16 levels¹². In fetal mesenchymal stem cells converted into neurons, the abstract reports lower levels of the senescence markers p21 and beta-galactosidase for AEDG and KED, but not for EDR¹³.

Both peptides are also central to the group's mechanistic hypothesis: that ultrashort peptides enter cells, possibly through amino-acid and peptide transporters, and bind DNA or histones to change gene expression. Docking studies placed EDR at promoter sequences of genes such as CASP3, APOE and SOD2¹¹, and ranked EDR and other ultrashort peptides as efficient ligands of the LAT1, LAT2 and PEPT1 transporters¹⁴. These are computational predictions that still need direct experimental confirmation.

Limitations of the evidence

The biggest difference between these peptides and mainstream drug candidates is the evidence base. Nearly every Epitalon and Pinealon study traces back to Khavinson's institute or close collaborators, often in a few Russian journals. For Epitalon, independent cell studies now exist⁴, but a 2026 narrative review found human evidence limited to small physiological or biomarker studies and an older retinitis pigmentosa study, with no adequately powered randomized trial and inadequate pharmacokinetic and long-term safety data¹⁵. For Pinealon, we found no independent replication in PubMed-indexed research.

• Many endpoints are surrogate markers, such as reactive oxygen species, spine counts and gene expression, rather than functional outcomes.
• Mechanistic claims rely heavily on molecular docking.
• Some results conflict across models, such as Epitalon and melatonin^6,7.
• Neither peptide is approved by the FDA or the European Medicines Agency.

Choosing between Epitalon and Pinealon for research

The two peptides answer different questions. Epitalon suits work on telomere maintenance, cellular senescence and pineal or circadian endpoints; Pinealon suits work on neuronal oxidative stress and synaptic models. Both sit in our bioregulators range as Epithalon and Pinealon, and Pinealon is also part of the Semax / Selank / Pinealon Set.

Every Peptides Only lot is independently tested and ships from the USA with a lot-matched certificate of analysis showing HPLC purity and mass-spec identity, published in our certificate library. For the neuropeptides often studied alongside Pinealon, see Semax vs Selank.